NPJ Breast Cancer最新文献

{"title":"SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.","authors":"François-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, Adam M Brufsky, Stephen Chia, Javier Cortes, Massimo Cristofanilli, Giuseppe Curigliano, Shaheenah Dawood, Peter A Fasching, Lorenzo Gerratana, Antonio Giordano, Michail Ignatiadis, Hiroji Iwata, Wolfgang Janni, Elgene Lim, Kevin Kalinsky, Cynthia X Ma, Erica L Mayer, Arielle J Medford, Jason A Mouabbi, Joyce O'Shaughnessy, Yeon Hee Park, Javier Pascual, Pedram Razavi, Sarah Sammons, José Luis Sandoval, Luisana Sisca, Paolo Tarantino, Seth A Wander, Gustavo Werutsky, Nicholas A Turner","doi":"10.1038/s41523-026-00967-4","DOIUrl":"10.1038/s41523-026-00967-4","url":null,"abstract":"","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"12 1","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13247249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status.","authors":"Kei Kawashima, Masanori Oshi, Akimitsu Yamada, Kazutaka Narui, Zunairah Shah, Thaer Khoury, Itaru Endo, Kazuaki Takabe","doi":"10.1038/s41523-026-00981-6","DOIUrl":"10.1038/s41523-026-00981-6","url":null,"abstract":"<p><p>Apocrine morphology is a distinctive histopathological feature of breast cancer associated with unique clinical behavior, particularly in estrogen receptor (ER)-negative tumors. However, its molecular basis remains unclear and its relevance in ER-positive breast cancer has not been systematically examined. We performed an integrative analysis of breast cancer patients from the SEER database (n = 226,584) and The Cancer Genome Atlas (TCGA; n = 1017), incorporating clinicopathological, transcriptomic, and genomic data. Apocrine carcinoma was associated with favorable prognosis in ER-negative but worse survival in ER-positive breast cancer. Molecular and AR-related classifications did not fully recapitulate apocrine morphology. In ER-negative tumors, apocrine morphology correlated with lower proliferation and reduced predicted chemotherapy sensitivity. Conversely, in ER-positive tumors, apocrine morphology was associated with increased proliferation, enhanced immune-related signaling, and greater genomic instability. In conclusion, apocrine morphology represents an ER-dependent biological state with distinct prognostic and molecular implications.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148194846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysis.","authors":"Mohammed N Abdelaziz, Sagad O O Mohamed, Mohammed Hesham Nagi, Ibrahim Saleh Alawadi, Youstina Mohsen, Sohaila Essam Ibrahim, Radwa M Abdelsattar, Asmaa N Abdelaziz, Mohamed Yasser, Sherif Wael, Hend A Abdelgawad, Magdy Shehab, Khaled M Abdelwahab, Omar Hamdy","doi":"10.1038/s41523-026-00984-3","DOIUrl":"10.1038/s41523-026-00984-3","url":null,"abstract":"<p><p>Targeted axillary dissection (TAD) is an innovative approach for axillary staging in breast cancer patients with initially node-positive disease that converts to clinically node-negative status after neoadjuvant therapy. Optimal marking and localization techniques remain undetermined. This systematic review and meta-analysis searched PubMed, Scopus, Cochrane Library, and Web of Science through April 2025, including 59 observational studies on TAD (marked/clipped node removal plus sentinel lymph node biopsy) in such patients. Primary outcomes were identification rate, false-negative rate (FNR), concordance, and diagnostic accuracy. Using R software with random-effects models and logit transformation, TAD achieved a pooled identification rate of 95.1% (95% CI: 93.2%-96.5%). Pooled FNR was 6.37% (95% CI: 5.02%-8.04%; I² = 0.0%), with overall diagnostic accuracy of 94.68% (95% CI: 91.70%-96.63%). Targeted and sentinel nodes concorded in 73.34% (95% CI: 69.58%-76.79%). Subgroup analyses showed comparable performance across marking (clip, carbon, magnetic, radioactive seeds) and localization techniques (wire-guided, radioactive, magnetic, ultrasound-guided), with no significant differences. TAD offers high identification rates, low FNRs, reliable staging, and acceptable accuracy, with consistent results enabling implementation using locally available technologies.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"12 1","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13241489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Expression of Concern: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer.","authors":"","doi":"10.1038/s41523-026-00988-z","DOIUrl":"10.1038/s41523-026-00988-z","url":null,"abstract":"","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"12 1","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13241480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-associated adipomes promote invadopodia formation and enhance metastatic potential in triple-negative breast cancer.","authors":"Hariprasad Thangavel, Dhanya Dhanyalayam, Kezia Lizardo, Shivani Bansal, Junfeng Ma, Robert Glazer, Jyothi Nagajyothi","doi":"10.1038/s41523-026-00985-2","DOIUrl":"10.1038/s41523-026-00985-2","url":null,"abstract":"<p><p>Triple-Negative Breast Cancer (TNBC), which accounts for 15-20% of all breast cancer cases, remains one of the most aggressive and therapeutically challenging subtypes due to its lack of hormone receptors and HER2 expression, leaving chemotherapy as the primary treatment option. TNBC is characterized by early relapses and visceral metastasis, underscoring the urgent need to elucidate the mechanisms driving metastasis. The metastatic cascade begins with cancer cell invasion of the surrounding stroma, a process mediated by actin-rich protrusions called invadopodia that degrade the extracellular matrix (ECM). While the molecular machinery of invadopodia is well characterized, the upstream tumor microenvironment (TME) signals that regulate their formation remain poorly understood. In breast cancer, the TME is predominantly composed of mammary adipose tissue, where adipocytes undergo reprogramming into cancer-associated adipocytes (CAAs) that release extracellular vesicles, termed 'adipomes'. These adipomes serve as intercellular messengers, transferring bioactive molecules that can alter tumor cell behavior. Using a novel purification method, large (L)-adipomes were isolated from the plasma of TNBC subjects as well as from tumor-associated mammary fat (TAMF) using a murine TNBC model (EO771-C57BL/6) to investigate their role in invasion. Circulating L-adipomes from metastatic TNBC subjects induced epithelial-to-mesenchymal transition (EMT) and stemness signaling and promoted invadopodia formation in human non-tumorigenic breast epithelial cells, while TAMF-derived L-adipomes from metastatic-stage mice were enriched in phospholipids and promoted transcriptional and functional reprogramming in murine TNBC cells. Integrated transcriptomic and proteomic analyses revealed that adipomes activate stress-responsive MAPK signaling and upregulate proteins involved in actin cytoskeletal remodeling, mitochondrial metabolism, and translational machinery, pathways known to support invadopodia formation and extracellular matrix (ECM) degradation. Together, these findings establish adipocyte-derived adipomes as potent regulators of TNBC invasion and metastasis and reveal a previously unrecognized tumor-adipocyte signaling axis that may present new opportunities for therapeutic targeting.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13542080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.","authors":"Monique Celeste Tavares, Flávia C Balint, Romualdo Barroso-Sousa, Laura Testa, Pablo Mandó, Natália C Nunes, Sergio Alejandro Mazzotta, Micaela Rigesti, Isadora M Sousa, Matheus O Andrade, Mariana Gouveia, Fernanda Madasi, José Bines, Rafael D P Ferreira, Daniela D Rosa, Candice L Santos, Mariana R Monteiro, Zenaide S Souza, Daniele Assad-Suzuki, Carlos H Dos Anjos, Débora M Gagliato, Ana Maria U Gomes, Bruna M Zucchetti, Anezka Ferrari, Mayana L Brito, Maria Marcela F Monteiro, Gilmara Resende, Noele J B Gomes, Maria Victoria Costanzo, Solange Moraes Sanches, Vladmir C Lima, Jose Claudio Casali Rocha, Elizabeth Santana Dos Santos, Fabiana B Makdissi, Paulo M Hoff, Maria Del Pilar Estevez-Diz, Renata Colombo Bonadio","doi":"10.1038/s41523-026-00966-5","DOIUrl":"10.1038/s41523-026-00966-5","url":null,"abstract":"<p><p>Neoadjuvant pembrolizumab plus chemotherapy improves outcomes in early triple-negative breast cancer, but real-world evidence in patients with pathogenic BRCA1/2 variants remains limited. We analyzed 726 consecutively treated patients from the multicenter Neo-Real/GBECAM-0123 cohort who received at least one cycle of neoadjuvant pembrolizumab plus chemotherapy and underwent surgery. Patients with pathogenic BRCA1/2 variants (mBRCA) were identified in 105 of 600 tested patients (17.5%), corresponding to 14.5% of the overall cohort. Among mBRCA carriers, 82 (78.1%) had BRCA1 variants, 22 (21.0%) had BRCA2 variants, and in 1 patient (0.1%) the BRCA subtype was not specified. The comparator group comprised 621 patients with wild-type or unknown BRCA status (wt/unknown BRCA). Pathologic complete response was higher in the mBRCA group than in the wt/unknown BRCA group (74.0% vs 61.7%). With a median follow-up of 22 months, event-free and overall survival were favorable in both groups, with a non-significant trend toward improved event-free survival in the mBRCA group, particularly among patients with residual disease.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT Versus ¹⁸F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer.","authors":"Siji Zhu, Yihua Jin, Chao Hu, Yanli Fan, Xiaochun Fei, Jiajia Hu, Xiaosong Chen","doi":"10.1038/s41523-026-00983-4","DOIUrl":"10.1038/s41523-026-00983-4","url":null,"abstract":"<p><p>Accurate pathological response assessment of breast cancer following neoadjuvant therapy (NAT) is clinically critical but lacks robust imaging methods, so this study evaluated the diagnostic accuracy of ¹⁸F-fluorodeoxyglucose (FDG) PET/CT and ⁶⁸Ga-fibroblast activation protein inhibitor (FAPI) PET/CT in clinically node positive (cN+) breast cancer patients receiving NAT. This prospective study enrolled pathologically confirmed breast cancer patients who underwent NAT and both PET/CT scans preoperatively. The maximum standardized uptake value (SUVmax) was measured and an optimal ⁶⁸Ga-FAPI PET/CT threshold was determined via receiver operating characteristic (ROC) curve analysis. Among 75 patients, 33 (44.0%) achieved pathological complete response (pCR). SUVmax was significantly lower in the ypT0/Tis group compared to the ypT+ group for both ¹⁸F-FDG PET/CT (1.45 ± 0.55 vs. 5.19 ± 4.69, p < 0.001) and ⁶⁸Ga-FAPI PET/CT (1.59 ± 1.22 vs. 10.45 ± 8.54, p < 0.001). In the overall cohort, ⁶⁸Ga-FAPI PET/CT demonstrated higher sensitivity in detecting residual disease compared to ¹⁸F-FDG PET/CT (0.8 vs. 0.6, p = 0.003), with comparable specificity (0.9 vs. 0.9, p = 1.00). Exploratory subgroup analysis found that ⁶⁸Ga-FAPI PET/CT had superior sensitivity compared to ¹⁸F-FDG PET/CT in the hormone receptor-positive (HR + ) group (0.8 vs. 0.6, p = 0.02). These findings show that ⁶⁸Ga-FAPI PET/CT outperforms ¹⁸F-FDG PET/CT in identifying residual breast lesions after NAT in cN+ patients, particularly among HR+ patients, which would guide further treatment strategies after NAT.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13534706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylation profiling of normal tissue adjacent to breast tumors reveals two distinct groups with divergent tumor microenvironment features.","authors":"Hela Koka, Priscilla Ming Yi Lee, Bin Zhu, Feng Wang, Avraam Tapinos, Mustapha Abubakar, Difei Wang, Xiaoyu Wang, Xing Hua, Chad A Highfill, Li Feng, Tongwu Zhang, Cherry Wu, Koon Ho Tsang, Yee-Kei Tsoi, W C Chan, Sze Hong Law, Ray Ka Wai Hung, Gary M Tse, Kristine Jones, Aurelie Vogt, Amy Hutchinson, Belynda Hicks, Montserrat Garcia-Closas, Stephen J Chanock, David C Wedge, Lap Ah Tse, Xiaohong R Yang","doi":"10.1038/s41523-026-00944-x","DOIUrl":"10.1038/s41523-026-00944-x","url":null,"abstract":"<p><p>We previously identified diverse genetic evolutionary patterns in whole-genome sequencing of paired normal tissue adjacent to tumor (NAT) and tumor tissues from Hong Kong breast cancer (HKBC) patients. Here, we investigated whether DNA methylation (DNAm) contributes to NAT heterogeneity and shapes the tumor microenvironment (TME). Genome-wide DNAm profiling was performed on paired NAT and tumor tissues from 188 HKBC patients using the Infinium 850 K array. RNA-seq data were available for 76 NATs and 177 tumors. Cellular composition was inferred using MethylCIBERSORT, CIBERSORTx, and EpiDISH, and histopathologic features were assessed on 115 H&E-stained sections. Unsupervised clustering identified two distinct NAT subtypes with divergent TME characteristics. Cluster 1 (N = 139) showed higher epithelial and fibroblast content and enrichment of estrogen response pathways. Cluster 2 (N = 49) exhibited an immune-metabolic phenotype characterized by increased fat and immune cells, stromal disruption, inflammatory pathway activation, and greater macrophage infiltration. Cluster 2 patients also demonstrated significantly younger epigenetic age estimated using multiple epigenetic clocks. These DNAm-defined NAT subtypes and associated TME features were validated in 97 NAT samples from TCGA breast cancer patients. Overall, our findings identify DNAm-driven NAT heterogeneity with distinct TME landscapes, providing new insights into field cancerization and tumor evolution in breast cancer.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13534499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy.","authors":"Koen Kwakkenbos, Nadine S van den Ende, Bernadette A M Heemskerk-Gerritsen, Jifke F Veenland, Agnes Jager, Carolien H M van Deurzen","doi":"10.1038/s41523-026-00979-0","DOIUrl":"10.1038/s41523-026-00979-0","url":null,"abstract":"<p><p>The binary pathological complete response (pCR) status of triple-negative breast cancer (TNBC) patients after neoadjuvant chemotherapy (NAC) inadequately captures risk heterogeneity for prognosis. Therefore, this study aimed to develop a machine learning-based survival model to predict individualized overall survival (OS) in TNBC patients with pCR after NAC. This retrospective study utilized a Dutch nationwide cohort of TNBC patients, diagnosed between 2013 and 2021. We trained a survival model on the data using nested 5-fold cross-validation. Patients were stratified into a low- and high-risk group, based on the predicted survival probabilities. A total of 2642 patients with a pCR post-NAC were included, of whom 2620 were used in the final analysis. The survival model achieved good discrimination (C-index 0.754). Risk stratification identified a high-risk subgroup (n = 495, 18.9%) with significantly worse survival compared to the low-risk group (5-year OS 85.2% vs. 96.7%, log-rank P < 0.001). Pre-treatment nodal status (cN) was the strongest predictor, followed by age and clinical tumor stage (cT). This nationwide analysis demonstrates that TNBC patients achieving pCR remain a heterogeneous group with distinct survival outcomes. Machine learning-based survival modeling may enable individualized risk prediction using routinely collected clinical variables and may guide future post-surgical treatment escalation for high-risk TNBC patients despite pCR.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neighborhood deprivation and oncotype DX recurrence scores among Black and White women: the interplay between race, place, and tumor biology.","authors":"Jasmine M Miller-Kleinhenz, Lauren E Barber, Maret L Maliniak, Lindsay J Collin, Demetria J Smith-Graziani, Jeffery M Switchenko, Kevin C Ward, Lauren E McCullough","doi":"10.1038/s41523-026-00978-1","DOIUrl":"10.1038/s41523-026-00978-1","url":null,"abstract":"<p><p>Breast cancer mortality disparities have persisted between non-Hispanic Black (NHB) and non-Hispanic White (NHW) women, even among those with prognostically favorable disease. The Oncotype DX Recurrence Score (ODX RS) is a gene expression panel used to identify estrogen receptor (ER)-positive breast cancers with aggressive tumor biology, and prior studies suggest higher scores among Black women and in lower-socioeconomic areas. We examined associations of neighborhood deprivation with ODX RS among 11,377 NHB and NHW women diagnosed with ER-positive breast cancer (stage I-IIIa, ≤3 lymph nodes) between 2010-2017 in the Georgia Cancer Registry. The Neighborhood Deprivation Index (NDI), derived via principal component analysis of American Community Survey block-group data, was assessed in quartiles. Prevalence ratios (PR) and 95% confidence intervals (CI) were estimated for high-risk (≥31) versus low-risk (<18) ODX RS. Living in the most deprived neighborhoods was modestly associated with high-risk ODX RS overall (PR = 1.08, 95% CI 0.90-1.30) and among NHW women (PR = 1.12, 95% CI 0.87-1.44), but not among NHB women (PR = 1.01, 95% CI 0.77-1.33). NHB women in the least deprived neighborhoods had the highest prevalence of high-risk ODX RS relative to NHW women in those neighborhoods (PR = 1.92, 95% CI 1.53-2.41). These findings suggest neighborhood deprivation does not explain racial differences in genomic risk.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}